Skip to content

72 hours Moisturization Potential of Piramal whipped dewy cream

A clinical study to evaluate the 72 hours Moisturization Potential of Piramal whipped dewy cream (R&D/STB/25/34) on healthy human volunteers - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102491
Enrollment
32
Registered
2026-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: whipped dewy cream: Dose: Gently massage approx. 1 drop of over one block as assigned (forearm) Route of Administration: Topical Duration: 72 hour Control Intervention1:

Sponsors

Piramal Pharma Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female with age 18-45. 2) Subject with normal to dry skin. 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last years, or any other confounding skin condition. 3. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 4. Have participated in any interventional clinical trial in the previous 90 days. 5. Have a known sensitivity to any of the constituents of the test product 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids

Design outcomes

Primary

MeasureTime frame
Change in hydration Change in TEWL Timepoint: T0min, T30min, T+2hrs, T+8hrs, T+24hrs, T+ 48hours, T+72hrs

Secondary

MeasureTime frame
Timepoint:

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026